Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown benefits in improving cardiovascular (CV) outcomes in patients with heart failure (HF) and may mitigate symptom progression in myocardial infarction (MI). However, their effectiveness in patients with type 2 diabetes and MI un...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | American Journal of Preventive Cardiology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666667724002964 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841558867042893824 |
|---|---|
| author | Huzaifa Ul Haq Ansari Muhammad Ammar Samad Eman Mahboob Eeshal Zulfiqar Shurjeel Uddin Qazi Areeba Ahsan Mushood Ahmed Faizan Ahmed Raheel Ahmed Shafaqat Ali Mahboob Alam Jamal S. Rana Gregg C. Fonarow |
| author_facet | Huzaifa Ul Haq Ansari Muhammad Ammar Samad Eman Mahboob Eeshal Zulfiqar Shurjeel Uddin Qazi Areeba Ahsan Mushood Ahmed Faizan Ahmed Raheel Ahmed Shafaqat Ali Mahboob Alam Jamal S. Rana Gregg C. Fonarow |
| author_sort | Huzaifa Ul Haq Ansari |
| collection | DOAJ |
| description | Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown benefits in improving cardiovascular (CV) outcomes in patients with heart failure (HF) and may mitigate symptom progression in myocardial infarction (MI). However, their effectiveness in patients with type 2 diabetes and MI undergoing percutaneous coronary intervention (PCI) is unclear. Methods: To identify eligible studies, a comprehensive search of electronic databases, PubMed, Cochrane Library, Scopus and Embase, was conducted from inception until May 2024. Results were presented as risk ratios (RR) and their corresponding 95 % confidence intervals (CIs). Results: Our analysis included 8 observational studies comprising 24,229 patients. The results indicated that SGLT2i with PCI was associated with a significantly reduced risk of all-cause death (RR=0.61; 95 % CI=0.54 to 0.68), CV death (RR=0.46; 95 % CI=0.22 to 0.94), major adverse cardiovascular events (RR=0.80;95 % CI: 0.66 to 0.96), HF-related hospitalizations (RR=0.63; 95 % CI=0.44 to 0.90), stroke (RR=0.77; 95 % CI: 0.62 to 0.96) and acute kidney injury (RR=0.46; 95 % CI: 0.25 to 0.84) compared to PCI without SGLT2i use. However, the risk of revascularization remained comparable between the groups. Conclusion: Our study demonstrates that SGLT2i with PCI in patients with type 2 diabetes and MI are associated with improved CV outcomes compared to PCI without SGLT2i use. Randomized controlled trials are required to confirm the improvement in outcomes with SGLT2i therapy combined with PCI in patients with MI and diabetes. |
| format | Article |
| id | doaj-art-c22c10b5072c4688810dff9218034522 |
| institution | Kabale University |
| issn | 2666-6677 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Preventive Cardiology |
| spelling | doaj-art-c22c10b5072c4688810dff92180345222025-01-06T04:09:06ZengElsevierAmerican Journal of Preventive Cardiology2666-66772025-03-0121100927Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysisHuzaifa Ul Haq Ansari0Muhammad Ammar Samad1Eman Mahboob2Eeshal Zulfiqar3Shurjeel Uddin Qazi4Areeba Ahsan5Mushood Ahmed6Faizan Ahmed7Raheel Ahmed8Shafaqat Ali9Mahboob Alam10Jamal S. Rana11Gregg C. Fonarow12Dow University of Health Sciences, Karachi, PakistanDow University of Health Sciences, Karachi, PakistanDow University of Health Sciences, Karachi, PakistanDow University of Health Sciences, Karachi, PakistanDow University of Health Sciences, Karachi, PakistanFoundation University Medical College, Islamabad, PakistanRawalpindi Medical University, Rawalpindi, PakistanDivision of Cardiology, Duke University Hospital, Durham, NC, USADepartment of Cardiology, Royal Brompton Hospital, London, UK; National Heart and Lung Institute, Imperial College London, UK; Corresponding author at: National Heart and Lung Institute, Imperial College London, UK.Department of Cardiology, Louisiana State University, Shreveport, USADepartment of Cardiology, Baylor College of Medicine, Houston, TX, USADivision of Cardiology, Kaiser Permanente Northern California, Oakland, CA, USA; Division of Research, Kaiser Permanente Northern California, Oakland, CA, USAAhmanson-UCLA Cardiomyopathy Center, Division of Cardiology, University of California Los Angeles, Los Angeles, CA, USABackground: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown benefits in improving cardiovascular (CV) outcomes in patients with heart failure (HF) and may mitigate symptom progression in myocardial infarction (MI). However, their effectiveness in patients with type 2 diabetes and MI undergoing percutaneous coronary intervention (PCI) is unclear. Methods: To identify eligible studies, a comprehensive search of electronic databases, PubMed, Cochrane Library, Scopus and Embase, was conducted from inception until May 2024. Results were presented as risk ratios (RR) and their corresponding 95 % confidence intervals (CIs). Results: Our analysis included 8 observational studies comprising 24,229 patients. The results indicated that SGLT2i with PCI was associated with a significantly reduced risk of all-cause death (RR=0.61; 95 % CI=0.54 to 0.68), CV death (RR=0.46; 95 % CI=0.22 to 0.94), major adverse cardiovascular events (RR=0.80;95 % CI: 0.66 to 0.96), HF-related hospitalizations (RR=0.63; 95 % CI=0.44 to 0.90), stroke (RR=0.77; 95 % CI: 0.62 to 0.96) and acute kidney injury (RR=0.46; 95 % CI: 0.25 to 0.84) compared to PCI without SGLT2i use. However, the risk of revascularization remained comparable between the groups. Conclusion: Our study demonstrates that SGLT2i with PCI in patients with type 2 diabetes and MI are associated with improved CV outcomes compared to PCI without SGLT2i use. Randomized controlled trials are required to confirm the improvement in outcomes with SGLT2i therapy combined with PCI in patients with MI and diabetes.http://www.sciencedirect.com/science/article/pii/S2666667724002964Sodium-glucose co-transporter 2 inhibitorsType 2 diabetesMyocardial infarctionPercutaneous coronary intervention |
| spellingShingle | Huzaifa Ul Haq Ansari Muhammad Ammar Samad Eman Mahboob Eeshal Zulfiqar Shurjeel Uddin Qazi Areeba Ahsan Mushood Ahmed Faizan Ahmed Raheel Ahmed Shafaqat Ali Mahboob Alam Jamal S. Rana Gregg C. Fonarow Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis American Journal of Preventive Cardiology Sodium-glucose co-transporter 2 inhibitors Type 2 diabetes Myocardial infarction Percutaneous coronary intervention |
| title | Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis |
| title_full | Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis |
| title_fullStr | Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis |
| title_full_unstemmed | Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis |
| title_short | Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis |
| title_sort | sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention a systematic review and meta analysis |
| topic | Sodium-glucose co-transporter 2 inhibitors Type 2 diabetes Myocardial infarction Percutaneous coronary intervention |
| url | http://www.sciencedirect.com/science/article/pii/S2666667724002964 |
| work_keys_str_mv | AT huzaifaulhaqansari sodiumglucosecotransporter2inhibitorsinpatientswithtype2diabetesandmyocardialinfarctionundergoingpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT muhammadammarsamad sodiumglucosecotransporter2inhibitorsinpatientswithtype2diabetesandmyocardialinfarctionundergoingpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT emanmahboob sodiumglucosecotransporter2inhibitorsinpatientswithtype2diabetesandmyocardialinfarctionundergoingpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT eeshalzulfiqar sodiumglucosecotransporter2inhibitorsinpatientswithtype2diabetesandmyocardialinfarctionundergoingpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT shurjeeluddinqazi sodiumglucosecotransporter2inhibitorsinpatientswithtype2diabetesandmyocardialinfarctionundergoingpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT areebaahsan sodiumglucosecotransporter2inhibitorsinpatientswithtype2diabetesandmyocardialinfarctionundergoingpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT mushoodahmed sodiumglucosecotransporter2inhibitorsinpatientswithtype2diabetesandmyocardialinfarctionundergoingpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT faizanahmed sodiumglucosecotransporter2inhibitorsinpatientswithtype2diabetesandmyocardialinfarctionundergoingpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT raheelahmed sodiumglucosecotransporter2inhibitorsinpatientswithtype2diabetesandmyocardialinfarctionundergoingpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT shafaqatali sodiumglucosecotransporter2inhibitorsinpatientswithtype2diabetesandmyocardialinfarctionundergoingpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT mahboobalam sodiumglucosecotransporter2inhibitorsinpatientswithtype2diabetesandmyocardialinfarctionundergoingpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT jamalsrana sodiumglucosecotransporter2inhibitorsinpatientswithtype2diabetesandmyocardialinfarctionundergoingpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis AT greggcfonarow sodiumglucosecotransporter2inhibitorsinpatientswithtype2diabetesandmyocardialinfarctionundergoingpercutaneouscoronaryinterventionasystematicreviewandmetaanalysis |